Galderma drug passes PhIII in rare skin disease, setting the stage for approval request

Working to catch up to Leo Pharma in the IL-13 itchy skin field, dermatology behemoth Galderma is one step closer to regulators’ doorsteps for a monoclonal antibody it licensed from Chugai Pharmaceutical.

The former Nestlé Skin Health unit said Wednesday that the drug, named nemolizumab, passed muster in one...

Click to view original post